BPGbio Receives FDA Rare Pediatric Disease Designation for its ...
WEB6 days ago — Company is planning a potential pivotal trial of BPM31510IV targeting multiple CoQ10 deficiency mutations at multiple US and EU sites. BOSTON, MA., Sept. 30, 2024 – BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric ...
BPGbio to Present Novel Drug Target for Huntington’s Disease …
WEB3 days ago — BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically ...
News & Updates - BPGbio
WEB6 days ago — August 27, 2024 | Media, News and Updates. AI And Biotech: How Companies Can Demonstrate Value To Investors. read more. August 26, 2024 | Media, News and Updates, Press Releases. BPGbio to Present on its First-in-Class E2-based Approach to Targeted Protein Degradation at 15th …
BPGbio’s mitochondrial disorder drug gets paediatric disease status
WEB5 days ago — BPGbio has received a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for BPM31510IV to treat primary coenzyme Q10 deficiency, an ultra-rare mitochondrial disorder.
BPGbio Receives FDA Rare Pediatric Disease Designation for its ...
WEB6 days ago — BOSTON, September 30, 2024--BPGbio received an FDA Rare Pediatric Disease Designation for its potential treatment for primary coenzyme Q10 deficiency. News Today's news
BPGbio | Biology-First AI-Powered Clinical Stage Biopharma …
WEBWith five drug candidates phase II/III ready and over a hundred drug and diagnostic targets discovered, BPGbio is leading the field in putting the first AI-developed drug onto the market and proving the concept of AI drug discovery.
BPGbio Announces First Patients Dosed in Phase 2 Trial of AI …
WEBJun 6, 2023 — BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially.
BPGbio Wins 2023 BioTech Breakthrough Award for ... - Business …
WEBNov 8, 2023 — BOSTON-- ( BUSINESS WIRE )-- BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced it has been recognized with the...
BPGbio to Present Research and Pipeline Advancements on …
WEBAug 19, 2024 — BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics...
BPGbio to Present on its First-in-Class E2-based Approach to …
WEBBOSTON, MASS., Aug. 26, 2024 – BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that Vivek K. Vishnudas, Ph.D., Chief Technology Officer and R&D Site Head at BPGbio, will present on the company’s Protein Homeostasis program at the 15th ...